T-cell regulation during viral and nonviral asthma exacerbations

• Published in: Journal of allergy and clinical immunology Vol. 136; no. 1; pp. 194 - 197.e9
• Main Authors: Wegrzyn, Agnieszka S., Jakiela, Bogdan, Rückert, Beate, Jutel, Marek, Akdis, Mübeccel, Sanak, Marek, Akdis, Cezmi A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2015; Elsevier Limited
• Subjects: Adult; Allergy and Immunology; Antigens, CD - metabolism; Asthma; Asthma - complications; Asthma - immunology; Asthma - virology; Cell Movement; Cell Separation; Cells, Cultured; Cytokines; Cytokines - metabolism; Disease Progression; Drug dosages; Female; Flow Cytometry - methods; Forkhead Transcription Factors - metabolism; Humans; Ikaros Transcription Factor - metabolism; Immunophenotyping; Lymphocytes; Male; Middle Aged; Receptors, CCR7 - metabolism; Software; Spirometry; T-Lymphocyte Subsets - immunology; T-Lymphocytes, Regulatory - immunology; Transcription factors; Virus Diseases - complications; Virus Diseases - immunology; Virus Diseases - virology; Viruses - immunology
• ISSN: 0091-6749; 1097-6825; 1097-6825
• DOI: 10.1016/j.jaci.2014.12.1866

To the Editor: Asthma is a common chronic inflammatory disease of the airways characterized by recurrent episodes of airway inflammation and following cycles of tissue repair and regeneration.1Asthma exacerbations are defined as episodes of progressive increase in shortness of breath, cough, wheezing, and chest tightness, or a combination of these symptoms, accompanied by decreases in expiratory airflow that can be quantified by measurement of lung function. Characteristic Stable asthma Viral exacerbated asthma[low *] Nonviral exacerbated asthma Healthy controls n 21 9 7 13 Sex: male/female 5/16 4/5 3/4 7/6 Age (y), mean ± SD 44.77 ± 13.75 40.56 ± 13.57 59.57 ± 7.76 45 ± 13.53 Duration of asthma (y), mean ± SD 12.82 ± 14.57 10.44 ± 8.47 14.29 ± 15.63 NA Total serum IgE (kU/dL), median (IQR) 67.0 (24.0-191) 71 (35-298) 411 (203-598) NA Peripheral blood eosinophilia (cells per mm3), median (IQR) 364 (140-518) 240 (82-502) 426 (199-630) NA FEV1% 91.55 ± 11.10 74.31 ± 8.45 75.68 ± 8.38 NA Hypersensitivity to nonsteroidal anti-inflammatory drugs, % 59.1 66.7 42.9 NA Chronic rhinosinusitis, % 95.5 88.9 57.1 0 Positive skin test results with common allergens, % 40.1 33.3 71 NA GINA asthma severity, median (IQR) 2 (1-3) 2 (1-3) 4 (2-4) NA Oral corticosteroids (%, average dose mg) 9.0, 16 11.1, 8 14.3, 4 0% Inhalatory corticosteroids (%, average dose [micro]g, [range]) 86.4, 500 (200-1000) 88.9, 960 (560-1000) 100, 1000 (500-1800) 0% Asthma control test, median (IQR) 21 (17-25) 23 (16-25) 17 (8-21) NA Table E1 Characteristics of study subjects Oral corticosteroids recalculated for methylprednisolone equivalent; inhaled corticosteroids recalculated for fluticasone equivalent.IQR, Interquartile range; FEV1%, predicted percentage of FEV1; GINA, Global Initiative for Asthma; NA, not applicable/available.